• Ocular Therapeutix will attend the UBS Global Biopharma Conference in London on Nov. 17, 2026; CEO Pravin U. Dugel will present.
• Chief Scientific Officer Jeffrey S. Heier will present at the Empire Forum in New York on Nov. 5, 2026.
• Participation in OSN New York & OSN New York Retina, Nov. 6-8, 2026, includes a Nov. 7 symposium on nAMD management.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocular Therapeutix Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610290700PRIMZONEFULLFEED9855899) on October 29, 2026, and is solely responsible for the information contained therein.